Immunotherapy has made remarkable strides in cancer therapy over the past decade.
However, such emerging therapy still suffers from the low response rates and immune …

Abstract mRNA vaccines have evolved from being a mere curiosity to emerging as COVID-
19 vaccine front-runners. Recent advancements in the field of RNA technology, vaccinology …

The successful clinical application of immune checkpoint blockade (ICB) and chimeric
antigen receptor T cells (CAR-T) therapeutics has attracted extensive attention to …

Nanomedicine has made significant advances in clinical applications since the late-20th
century, in part due to its distinct advantages in biocompatibility, potency, and novel …

Nanoparticle-based therapeutics and diagnostics are commonly referred to as
nanomedicine and may significantly impact the future of healthcare. However, the clinical …

During the last two decades, there has been broad interest in RNA-based technologies for
the development of prophylactic and therapeutic vaccines. Preclinical and clinical trials have …

Chimeric antigen receptor (CAR) T cell therapy relies on the ex vivo manipulation of patient
T cells to create potent, cancer-targeting therapies, shown to be capable of inducing …

Cancer vaccines aim at eliciting tumor‐specific responses for the immune system to identify
and eradicate malignant tumor cells while sparing the normal tissues. Furthermore, cancer …

Research on the use of biodegradable polymers for drug delivery has been ongoing since
they were first used as bioresorbable surgical devices in the 1980s. For tissue engineering …

Immunotherapy has recently garnered plenty of attention to improve the clinical outcomes in
the treatment of various diseases. However, owing to the dynamic nature of the immune …